Relapse, rebound, and psoriasis adverse events: An advisory group report
- 30 April 2006
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 54 (4), S171-S181
- https://doi.org/10.1016/j.jaad.2005.10.029
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque PsoriasisThe New England Journal of Medicine, 2003
- Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque PsoriasisJournal of Cutaneous Medicine and Surgery, 2003
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Generalized pustular psoriasis following a short course of cyclosporin (Neoral)British Journal of Dermatology, 1998
- The course of psoriasisClinics in Dermatology, 1997
- Cyclosporine as maintenance therapy in patients with severe psoriasisJournal of the American Academy of Dermatology, 1997
- Generalized pustular psoriasis in relation to withdrawal of cyclosporin ABritish Journal of Dermatology, 1990
- LIFE-THREATENING PSORIASIS RELAPSE ON WITHDRAWAL OF CYCLOSPORINThe Lancet, 1988
- Low-dose cyclosporin A in severe psoriasis. A double-blind studyBritish Journal of Dermatology, 1988